Evidence map›Paper›PMID 41974963›Full record

ArticleNature immunology2026

Purine salvage pathway protects CD8

Masaki Tajima, He Hao, Baihao Zhang, Yuta Matsuoka, Kazuhiro Sonomura, Koshi Imami, Yosuke Isobe, Rae Maeda, Yu-Hsien Lin, Akihiro Shimba and 20 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Masaki TajimaDivision of Integrated High-Order Regulatory Systems, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. tajima.masaki.7r@kyoto-u.ac.jp.ORCID http://orcid.org/0000-0003-3407-0229
He Hao *Division of Integrated High-Order Regulatory Systems, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Baihao Zhang *Laboratory for Mucosal Immunity, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan.ORCID http://orcid.org/0000-0002-3456-2509
Yuta Matsuoka *Multi Omics Platform, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0001-9860-3851
Kazuhiro SonomuraCenter for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Koshi ImamiProteome Homeostasis Research Unit, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan.ORCID http://orcid.org/0000-0002-7451-4982
Yosuke IsobeLaboratory for Metabolomics, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan.
Rae MaedaMulti Omics Platform, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yu-Hsien LinDivision of Integrated High-Order Regulatory Systems, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-5303-1084
Akihiro ShimbaDivision of Integrated High-Order Regulatory Systems, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Ryoma KatoDivision of Integrated High-Order Regulatory Systems, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Pedro Henrique Costa CruzDivision of Integrated High-Order Regulatory Systems, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Sayaka WashizuDivision of Integrated High-Order Regulatory Systems, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yosuke IkejiriDivision of Integrated High-Order Regulatory Systems, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Akiyo MorinibuDivision of Integrated High-Order Regulatory Systems, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Clive Steven BarkerLaboratory for Integrative Genomics, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan.
Jun SeitaLaboratory for Integrative Genomics, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan.ORCID http://orcid.org/0000-0002-3008-3615
Yibo WuYCI Laboratory for Next-Generation Proteomics, Center for Integrative Medical Sciences, RIKEN Yokohama Institute, Yokohama, Japan.
Satomi ItoLaboratory for Mucosal Immunity, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan.
Seiko NarushimaLaboratory for Mucosal Immunity, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan.
Rei NakanoLaboratory for Mucosal Immunity, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan.ORCID http://orcid.org/0000-0003-0255-6347
Mikako MaruyaLaboratory for Mucosal Immunity, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan.
Wakana KobayashiLaboratory for Mucosal Immunity, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan.
Sai Shanmukha Priya NarayananDivision of Integrated High-Order Regulatory Systems, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0009-0006-8774-6746
Jumana ShaheenDivision of Integrated High-Order Regulatory Systems, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0009-0006-8997-7337
Hiroyuki NeyamaMulti Omics Platform, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Ken-Ichi YamadaDepartment of Molecular Pathobiology, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.ORCID http://orcid.org/0000-0003-2100-8477
Makoto AritaLaboratory for Metabolomics, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan.ORCID http://orcid.org/0000-0001-9902-0463
Yuki SugiuraMulti Omics Platform, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Sidonia FagarasanDivision of Integrated High-Order Regulatory Systems, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. sidonia.fagarasan@riken.jp.ORCID http://orcid.org/0000-0003-2086-6402

Funding

Japan Agency for Medical Research and Development (AMED) 25zf0127003Japan Agency for Medical Research and Development (AMED) 25zf0127007Japan Agency for Medical Research and Development (AMED) JP25gm2010001MEXT | Japan Science and Technology Agency (JST) JPMJSP2110MEXT | Japan Society for the Promotion of Science (JSPS) 19K16881MEXT | Japan Society for the Promotion of Science (JSPS) 22K15501MEXT | Japan Society for the Promotion of Science (JSPS) 24K10092MEXT | Japan Society for the Promotion of Science (JSPS) 25H01031MEXT | JST | Core Research for Evolutional Science and Technology (CREST) JPMJCR24T6MEXT | JST | Exploratory Research for Advanced Technology (ERATO) JPMJER2101
6 · The paper itself

Abstract

Metabolic stress from a high-fat diet (HFD) impairs antitumor immunity through persistent metabolic rewiring, but its effects and long-term impact on CD8

Indexed as

CD8-Positive T-LymphocytesPurinesStress, PhysiologicalAnimalsDiet, High-FatLipid PeroxidationMiceMice, Inbred C57BLOxidative StressXanthinepurinePurinesXanthine

Identifiers

PMID41974963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.